Our (e)Books and (e)Journals

IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.



Latin American and Caribbean Research: Major Contributions in the Fight Against Alzheimer’s Disease

August 2, 2021 - Amsterdam, NL – Every year there are nearly ten million new cases of dementia globally, of which Alzheimer’s disease (AD) is the most common form, accounting for around 60–70% of cases. This special supplement, published in the Journal of Alzheimer’s Disease, focuses on the challenges posed by brain disease and presents significant research contributions from Latin America and the Caribbean that address these challenges to help improve the lives of individuals with AD.

August 2, 2021

When We Are Born Can Influence How Mentally Fit We Will Be in Old Age

July 29, 2021 - Prague, Czechia – According to a study published in Journal of Alzheimer's Disease, people born in winter seem to carry a life-long disadvantage in cognitive ageing. Specifically, their cognitive skills are lower when compared to people born in other seasons, even when taking into account other influencing characteristics, such as their education, depression or cardiovascular diseases.

July 29, 2021

Latest Journal Citation Reports Shows Significant Impact Factor Increases for IOS Press Journals

July 28, 2021 - Amsterdam, NL – IOS Press, an independent international publisher of scientific, technical, and medical (STM) journals and books, is pleased to announce significant increases in the Journal Impact Factors (JIFs) of two of its flagship journals in neurogenerative diseases. The Journal of Parkinson’s Disease JIF has increased by 7.5% to 5.568, positioning it in the first quartile of Neuroscience journals with a ranking of 62 among 270 journals in that category. The Journal of Alzheimer’s Disease, the most highly cited journal devoted exclusively to this disease, rose by an impressive 14.4% to 4.472.

July 28, 2021

Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors

July 27, 2021 - St. Louis, MO, USA – Keystone Bio, a biotechnology company, is a frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis (Pg) and is releasing groundbreaking data that shows bacterial toxic proteins from Pg in the mouth are released into the blood and cross the blood-brain barrier (BBB) as the major driver of sporadic Alzheimer’s disease (AD) and chronic inflammation.

July 27, 2021